Lexaria Bioscience (NASDAQ:LEXX) Raised to “Sell” at Wall Street Zen

Lexaria Bioscience (NASDAQ:LEXX) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Lexaria Bioscience has an average rating of “Hold” and an average price target of $22.50.

Lexaria Bioscience Stock Performance

NASDAQ:LEXX opened at $3.32 on Friday. Lexaria Bioscience has a 12 month low of $2.77 and a 12 month high of $21.60. The stock has a market capitalization of $7.01 million, a price-to-earnings ratio of -0.65 and a beta of 0.61. The firm has a fifty day simple moving average of $6.76 and a two-hundred day simple moving average of $9.04.

Lexaria Bioscience (NASDAQ:LEXX) last posted its quarterly earnings results on Monday, July 13th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Equities analysts predict that Lexaria Bioscience will post -4.05 earnings per share for the current fiscal year.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the way active pharmaceutical and nutritional compounds are absorbed and used by the body. Its principal technology, DehydraTECH, is intended to enhance the delivery, bioavailability, and performance of orally administered compounds.

The company has investigated DehydraTECH applications involving cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, antiviral compounds, and other active ingredients.